ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 0695 • ACR Convergence 2024

    Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort

    Stefano Di Donato1, Marco Minerba2, Enrico De Lorenzis3, Collette Hartley4, Lesley-Anne Bissell5, Rebecca Ross6 and Francesco Del Galdo4, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2Campus Bio-Medico University of Rome, Taranto, United Kingdom, 3Catholic University of the Sacred Heart, Roma, Rome, Italy, 4University of Leeds, Leeds, United Kingdom, 5Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
  • Abstract Number: 0838 • ACR Convergence 2024

    The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS

    Kavya Sugur1, Emily Chong1, Srilakshmi Yalavarthi2, Katarina Kmetova3, Lyndsay Kluge1, Wenying Liang2, Cyrus Sarosh4, NaveenKumar Somanathapura K2, Jacqueline Madison2, Ajay Tambralli2, Jason Knight2 and Yu Zuo2, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 4University of Michigan, Temperance, MI

    Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…
  • Abstract Number: 0964 • ACR Convergence 2024

    Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model

    Maithri Aspari1, Voon Ong2, Klaus Soendergaard3, Esben Naeser4, Malene Hvid4, Angela Tam5, Shiwen Xu5, Christopher Denton6, David Abraham7, Bent Deleuran1 and Stinne Greisen8, 1Aarhus University, Aarhus, Denmark, 2University College London, London, England, United Kingdom, 3Aarhus University Hospital, Aarhus, Denmark, 4AARHUS UNIVERSITET, AARHUS C, Denmark, 5University College London, London, United Kingdom, 6University College London, Northwood, United Kingdom, 7UCL, London, United Kingdom, 8Aarhus University/Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
  • Abstract Number: 1281 • ACR Convergence 2024

    The Brazilian Registry of Juvenile Dermatomyositis: Relationship Between Ultraviolet Radiation and Laboratory Markers of Juvenile Dermatomyositis in a Tropical Country

    Beatriz Carneiro1, Adriana Elias2, Claudia Saad-Magalhaes3, Erick Kill2, Sylvia Farhat2, Teresa Robazzi4, Ana Julia Moraes5, Sheila Oliveira6, Luciana Carvalho7, Taciana Fernandes3, Carlos Rabello8, Maria Teresa Terreri9, Silvana Sacchetti10, Simone Appenzeller11, Clovis Silva12, Claudio Len13, Darcisio Antonio14, Iloite Scheibel15, Melissa Fraga16, Marcia Bandeira17, Andre Cavalcante18, Ana Paula Vecchi19, Roberto Marini20, Flavio Sztajnbok21, Nadia Aikawa22, lucia Maria Campos2, Katia Kozu2 and Maria Paula Ribeiro2, 1University of São Paulo, São Paulo, SP, Brazil, 2University of Sao Paulo, São Paulo, SP, 3São Paulo State University, Botucatu, 4University of Bahia, Salvador, 5Para Federal University, Belém do Pará, 6Rio de Janeiro Federal University, Rio de Janeiro, Brazil, 7University of São Paulo (Ribeirao Preto), Ribeirao Preto, 8Albert Sabin Children's Hospital, Fortaleza, 9UNIFESP, São Paulo, SP, Brazil, 10Santa Casa Medical School, São Paulo, SP, Brazil, 11Unicamp, Campinas, SP, Brazil, 12Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 13Federal University of Sao Paulo, São Paulo, SP, 14São Paulo State University, Botucatu, SP, Brazil, 15Conceição's Hospital of Porto Alegre, Porto Alegre, 16Universidade Federal de São Paulo, São Paulo, SP, Brazil, 17Pequeno Principe Hospital, Curitiba, 18Pernambuco Federal University, Recife, 19Children's Hospital of Goiania, Goiânia, 20Campinas State University, Campinas, 21UFRJ/UERJ, SAO PAULO, Brazil, 22Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil

    Background/Purpose: Ultraviolet (UV) waves are risk factors for juvenile dermatomyositis (JDM), when compared to other types of myositis without skin involvement. Patients with JDM have…
  • Abstract Number: 1553 • ACR Convergence 2024

    Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)

    Torsten Witte1, Ruth Fernandez Ruiz2, Nadezda Abramova3, Dominika Weinelt3, Flavie Moreau4, Lena Klopp-Schulze5, Jamie Shaw6, Deborah Denis7 and Joerg Wenzel8, 1Dept of Immunology and Rheumatology, Hannover, Germany, 2Global Clinical Development, EMD Serono, Billerica, MA, 3Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, 4Global Biostatistics, EMD Serono, Billerica, MA, 5Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, 6Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, 7EMD Serono, Rockland, MA, 8Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany

    Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…
  • Abstract Number: 1792 • ACR Convergence 2024

    CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus

    Lauren Robinson1, Preetha Balasubramanian2, Zurong Wan2, Juan Rodriguez Alcazar2, Marina Lima Silva Santos2, Lynnette Walters3, Jeanine Baisch2, Karen Onel4, Tracey Wright5, Virginia Pascual6 and Simone Caielli2, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Scottish Rite Hospital for Children, Allen, TX, 4HSS, New York, NY, 5UT Southwestern, Plano, TX, 6Weill Cornell Medical College, New York, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
  • Abstract Number: 2094 • ACR Convergence 2024

    Cross-sectional Associations of Radiographic Multiple Joint Osteoarthritis and Pain with Demographic and Clinical Characteristics: Design of a Multi-modal Study in Human and Pet Dogs

    Liubov Arbeeva1, Kelly Johnson2, Serena Savage-Guin3, Tessa Walker2, Masataka Enomoto4, Christina Stevens4, Milja Koskinen4, Tracey Cole4, Savannah Aker4, Connor Thonen-Fleck4, Richard Loeser5, Jordan Renner2, Duncan Lascelles6, Yvonne Golightly7 and Amanda Nelson8, 1University of North Carolina, Chapel Hill, Carrboro, NC, 2Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill,, Chapel Hill, NC, 4Translational Research in Pain and Comparative Pain Research and Education Center, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, 5University of North Carolina, Chapel Hill, NC, 6North Carolina State University, Raleigh, NC, 7University of Nebraska Medical Center, Omaha, NE, 8University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Multiple joint osteoarthritis (MJOA) is a progressive, highly prevalent disease affecting millions of Americans and as well as pet dogs. This preliminary analysis sought…
  • Abstract Number: 2338 • ACR Convergence 2024

    TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis

    Lenche Kostadinova1, Brigid Wilson2, Hinnah Siddiqui2, Sara Behrens3, Angela Gupta4, Megan O'Mara3, Vicky Nahra5, Mahesha Makandura6, Shahdi Malakooti7, Maya Mattar8, David A Zidar1 and Donald D Anthony9, 1Louis Stokes VA Medical Center, cleveland, 2VA Northeast Ohio Healthcare System, Cleveland, 3CWRU, Cleveland, 4Brigham and Women's Faulkner Hospital, Rheumatology Center, Jamaica Plain, 5University Hospitals Cleveland Medical Center, Cleveland, 6Henri Ford Medical Center, Detroit, 7MetroHealth at Case Western Reserve University, Cleveland, 8Louis Stokes VA medical Center, Mayfield Heights, OH, 9Louis Stokes VA Medical Center/Metro Health, Cleveland

    Background/Purpose: Pathogenic inflammation in psoriatic arthritis (PsA) includes TNF pathway engagement, and this is associated with morbidity. Recently, we observed lower absolute lymphocyte count (ALC)…
  • Abstract Number: 2536 • ACR Convergence 2024

    Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium

    Kevin Bu1, Rebecca Blank2, Adam Cantor1, Alba Boix-Amoros3, Jose Scher4 and Jose Clemente1, and Accelerating Medicines Partnership and Immune-Mediated Diseases Network (AMP AIM), 1Icahn School of Medicine at Mount Sinai, New York, NY, 2NYU, New York, NY, 3Icahn School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY

    Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. Although AIMDs have distinct symptomatology, there is significant overlap in their treatment, suggesting overlap…
  • Abstract Number: 0109 • ACR Convergence 2024

    Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Rohan Willis1, Anne Tebo2, Leslie Skeith3, Nina Kello4, H Michael Belmont5, Paul Fortin6, Guilherme Ramires de Jesús7, David Branch8, Michelle Petri9, Jason Knight10, Reyhan Kose Cobanoglu11, Maria Laura Bertolaccini12, Hannah Cohen13, Robert Roubey14, Doruk Erkan15 and Danieli Andrade16, and on behalf of APS ACTION, 1University of Texas Medical Branch, Galveston, TX, 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 3University of Calgary, Calgary, ON, Canada, 4Northwell Health, Brooklyn, NY, 5NYU School of Medicine, New York, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 7Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 8University of Utah and Intermountain Healthcare, Salt Lake City, UT, 9Johns Hopkins University School of Medicine, Timonium, MD, 10University of Michigan, Ann Arbor, MI, 11Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 12King's College London, London, United Kingdom, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 15Hospital for Special Surgery, New York, NY, 16University of São Paulo, São Paulo, SP, Brazil

    Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…
  • Abstract Number: 0463 • ACR Convergence 2024

    Evaluation of Inflammatory Indices as Predictive Biomarkers of Carotid Plaque in Patients with Rheumatoid Arthritis

    Jose Antonio Davila Jimenez1, Dionicio Galarza-Delgado2, Iris Jazmín Colunga Pedraza3, jose Ramon Azpiri-Lopez4, Rosa Icela Arvizu-Rivera3, Jesus Cardenas-de la Garza5, Aleydis Gonzalez Melendez3, Andrea Guajardo Aldaco3, Maria F. Elizondo-Benitez6, Rebeca L. Polina-Lugo3 and Diego Salcedo-Almanza7, 1Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 2UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 5Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 6Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 7Division of Radiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk compared to the general population. All stages of the atherogenic process appear to…
  • Abstract Number: 0575 • ACR Convergence 2024

    Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA

    Kurt de Vlam1, Pieter Ruytinx2, Elien luyten2, Anouk Agten2, Frank Vandenabeele2 and Veerle somers2, 1Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, 2Universiteit Hasselt, Hasselt, Belgium

    Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…
  • Abstract Number: 0696 • ACR Convergence 2024

    MRI DAVIX Index Is an Imaging Biomarker for Endothelial Damage of Systemic Sclerosis Digital Ulcers

    Stefano Di Donato1, Rebecca Ross2, Yassir El-Sherbiny3, Riccardo Bixio4, Marco Minerba5, Christopher Wasson6, Jun Li7, Jochen SCHMITZ8, Sudha Visvanathan9 and Francesco Del Galdo6, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2Medicine and Health, University of Leeds, Leeds, United Kingdom, 3Nottingham Trent University, Nottingham, United Kingdom, 4University of Verona, Verona, Verona, Italy, 51. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, 6University of Leeds, Leeds, United Kingdom, 7Boehringer Ingelheim, Danbury, CT, 8Boehringer-Ingelheim, Ridgefield, CT, 9Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT

    Background/Purpose: Circulating endothelial cells (CEC) and their precursors have been shown to correlate to the severity of vascular manifestations in Systemic sclerosis1, such as Digital…
  • Abstract Number: 0849 • ACR Convergence 2024

    Effectiveness of Tocilizumab in Aortitis and Aneurysms Associated with Giant Cell Arteritis. Multicenter Open-label Study

    Adrián Martín-Gutiérrez1, Javier Loricera2, Carmen Secada Gómez3, Iñigo Hernández-Rodríguez4, Susana Romero Yuste5, Eugenio De Miguel6, Eva Galindez-Agirregoikoa7, ivan Ferraz-Amaro8, Julio Sánchez-Martín9, Patricia Moya Albarado10, Cristina Campos Fernández11, Fernando Lopez-Gutierrez12, Santos Castañeda13 and Ricardo Blanco-Alonso14, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 5Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, 6Hospital Universitario La Paz, Madrid, Spain, 7BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 8Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 9Hospital Universitario 12 de Octubre, Madrid, Spain, 10Hospital de San Pau, Barcelona, Spain, 11Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, 12Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 13Hospital Universitario de la Princesa, Madrid, Spain, 14Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Giant Cell Arteritis (GCA) was initially described involving mainly the extracranial branches of the carotid arteries. However, GCA also may involve the aorta (GCA-aortitis)…
  • Abstract Number: 1090 • ACR Convergence 2024

    Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy

    Naomi Schlesinger1, Katie Obermeyer2, Lissa Padnick-Silver2, Brian LaMoreaux3 and Peter Lipsky4, 1University of Utah, Salt Lake City, UT, 2Amgen, Inc., Thousand Oaks, CA, 3Amgen, Inc., Deerfield, IL, 4AMPEL BioSolutions, Charlottesville, VA

    Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD),1 with elevated serum urate (SU) and high flare frequency (≥3 flares/yr) contributing.2 The Fib-4 index, calculated from…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology